• Nexgel named Brian Kieser interim CEO effective Aug. 21, 2026 amid an operational integration push and broader strategic review.
• Kieser previously worked on integrating the BioNX Surgical division, manufacturing transition, commercialization, financing, strategic planning via Sequence Life Science partnership.
• Adam Levy will step down as CEO and leave the company effective Aug. 21, 2026.
• Levy will provide transition assistance for 90 days focused on knowledge transfer, key relationships, BioNX Surgical integration, public reporting support.
• A special board committee for strategic review, chaired by Kevin Harris with Steve Glassman, will oversee restructuring, liquidity, capital structure matters.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexgel Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608201605PRIMZONEFULLFEED9813812) on August 20, 2026, and is solely responsible for the information contained therein.